期刊文献+

MAGE-3原核表达载体的构建和表达 被引量:3

Construction of MAGE-3 Prokaryotic Expression Plasmid and Its Expression in Escherichia coli
下载PDF
导出
摘要 通过RT PCR扩增 95 7bp的MAGE 3全长编码序列 ,将该片段克隆至pGEX 4T 2原核表达载体 ,转化大肠杆菌BL 2 1,经IPTG诱导表达 ,并经 12 %SDS PAGE凝胶电泳 ,考马斯亮蓝染色及Westernblot鉴定 ,证明了目的基因的有效表达 ,目的蛋白高达细菌总蛋白的 32 %。表达产物经GlutathioneSepharose 4B纯化后 ,每 10 0mL菌液最终可获得 3mg的目的蛋白 ,蛋白纯度在 90 %以上。纯化的GST MAGE 3蛋白在体外冲击树突状细胞 。 To express the GST MAGE 3 protein in E.coli , and investigate the antitumor immune responses induced by Dendri tic cells(DCs) pulsed with GST MAGE 3 protein, the recombinant expression plasmid pGEX MAGE 3 was constructed by ligating MAGE 3 gene, which was amplified by RT PCR and confirmed by sequencing, and the pGEX 4T 2 vector. The recombinant plasmid was transformed into BL 21 E.coli . The expression of GST MAGE 3 was induced with IPTG. The GST MAGE 3 protein expressed as high as 32% of the total cellular protein. After purification with Glutathione Sepharose 4B, the purity of the protein was more than 90%, and 3mg GST MAGE 3 was obtained from 100 mL BL 21 lysate. Dendritic cells from gastric carcinoma patients were pulsed with GST MAGE 3 protein, and these DCs were used to stimulate the autologous T lymphocytes. After 7 days, the T lymphocytes cocultured with DCs pulsed with GST MAGE 3 antigen exhibited specific cytotoxicity against MAGE 3 positive SGC 7901 cells. It is concluded that the GST MAGE 3 protein are able to present antigen to T lymphocytes, activate antigen specific CTLs and induce special antitumor immune responses in vitro . Our results lay the groundwork for further research of the MAGE 3 vaccine.
出处 《生物工程学报》 CAS CSCD 北大核心 2003年第3期277-280,共4页 Chinese Journal of Biotechnology
关键词 原核表达 树突状细胞 细胞毒T淋巴细胞 免疫应答 表达载体 黑色素瘤抗原 GST MAGE 3 protein, prokaryotic expression, dendritic cells(DCs), cytotoxic T lymphocytes (CTLs), immune response
  • 相关文献

参考文献14

  • 1[1]Lucas S, De Smet C, Ardem K C et al. Identification of a new MAGE gene with tumor-specific expression by representational difference analysis. Cancer Res, 1998, 58(4): 743-752
  • 2[2]Tahara K, Mori M, Sadanaga N et al.Expression of the MAGE gene family in human hepatocellular carcinoma. Cancer, 1999, 85(6): 1234-1240
  • 3[3]Chen C H, Huang G T, Lee H S et al. High frequency of expression ofMAGE genes in human hepatocellular. Liver, 1999, 19(2):110-114
  • 4[4]Melief C J, Toes R E, Medema J P et al. Strategies for immunotherapy of cancer. AdvImmunol, 2000, 75: 235-282
  • 5[5]Chaux P, Vantomme V, Stroobant V et al. Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4+ T lymphocytes. J Exp Med, 1999, 189(5): 767-777
  • 6[6]Manici S, Sturniolo T,Imro M A et al. Melanoma cells present a MAGE-3 epitope to CD4+ cytotoxic T cells in association with histocompatibility leukocyte antigen DR11. J Exp Med, 1999, 189(5): 871-876
  • 7[7]Miconnet I, Servis C, Cerottini J C et al. Amino acid identity and/or position determines the proteasomal cleavage of the HLA-A 0201-restricted peptide tumor antigen MAGE-3 271-279. J Bio Chem, 2000, 275(35): 26892-26897
  • 8[8]Eifuku R, TakenoyamaM, Yoshino I et al. Analysis of MAGE-3 drived synthetic peptide as a human lung cancer antigen recognized by cytotoxic T lymphocytes. Int J Clin Oncol, 2001, 6(1): 34-39
  • 9[9]Toungouz M, Lambermont M, Velu T et al. Anti-tumor immunotherapy based ondendritic cells. J Soc Biol, 2001, 195(1):19-23
  • 10[10]Weber J S, Hua F L, Spears L et al. A phase I trial ofan HLA-A1 restricted MAGE-3 epitope peptide with incomplete freunds adjuvant in patients with resected high-risk melanoma. J Immunother, 1999, 22(5): 431-340

同被引文献16

  • 1张颖,陈世耀,刘天舒,王吉耀.黑色素瘤抗原基因的检测及其在胃癌中的表达[J].中国临床医学,2005,12(1):62-64. 被引量:6
  • 2李强,张轶,张奕,陈雪华,李建芳,顾琴龙,朱正纲,刘炳亚.小鼠I-A^kII类分子限制性MAGE-3T表位筛选[J].现代免疫学,2005,25(1):19-23. 被引量:3
  • 3周迈,彭吉润,王红霞,钟朝辉,郭晏同,潘秀英,冷希圣.利用质谱技术对肝癌组织中自然呈递的MAGE表位进行鉴定[J].世界华人消化杂志,2005,13(12):1395-1399. 被引量:14
  • 4赵时雨,楚胜华,袁先厚,江普查,李志强.黑色素瘤抗原-1,-3基因在脑胶质瘤中的表达及意义[J].中华神经医学杂志,2005,4(9):908-910. 被引量:4
  • 5Andersen MH, Keikavoussi P, Brocker EB, et al. Induction of systemic CTL responses in melanoma patients by dendritic cell vaccination: cessation of CTL responses is associated with disease progression[J]. Int J Cancer, 2001, 94(6): 820 -824.
  • 6Adanaga N, Nagashima H, Mashino K, et al. Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas[J]. Clin Cancer Res, 2001, 7(8): 2277 - 2284.
  • 7Nishiyama T, Tachibana M, Horiguchi Y, et al. Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen - A24 - specific MAGE - 3peptide[J]. Clin Cancer Res, 2001,7(1): 23 - 31.
  • 8Mokelo PH. Vaccines, coming of age after 200 years[J].FEMS Microbiol Rev, 2000, 24(1): 9 - 20.
  • 9Leitner WW, Ying H, Restifo NP. DNA and RNA based vaccines: principles, progress and prospects [ J ]. Vaccines,2000, 18(9 - 10): 765 - 777.
  • 10Haupt K, Roggendorf M, Mann K. The potential of DNA vaccination against tumor- associated antigens for antitumor therapy[J]. Exp Biol Med, 2002, 227(4): 227- 237.

引证文献3

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部